Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,346 result(s) found. Displaying page 1,507 of 2,218.
    «« First « Previous 1503  1504  1505  1506  1507  1508  1509  1510  1511  Next» Last»»
    EudraCT Number: 2017-002756-91 Sponsor Protocol Number: LPS14947 Start Date*: 2019-10-24
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabet...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005246-59 Sponsor Protocol Number: EO1115 Start Date*: 2016-03-23
    Sponsor Name:Michael Patrick Achiam
    Full Title: Endoscopic electroporation in esophageal cancer
    Medical condition: Esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002236-14 Sponsor Protocol Number: BI1160.206 Start Date*: 2015-10-28
    Sponsor Name:University Hospital Ulm
    Full Title: Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study
    Medical condition: left atrial thrombus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003319-76 Sponsor Protocol Number: MVDV/ER082019 Start Date*: 2019-10-09
    Sponsor Name:Univerity Hospitals Leuven
    Full Title: High volume PCEA versus PIEB for labor analgesia: a randomized, double-blind multicenter non-inferiority study in nulliparous women.
    Medical condition: providing adequate analgesia during child birth
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001406-42 Sponsor Protocol Number: 30032016 Start Date*: 2016-12-20
    Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde
    Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028577 Myeloproliferative disorder NOS LLT
    19.0 100000004864 10074689 Post polycythemia vera myelofibrosis LLT
    19.0 100000004864 10028576 Myeloproliferative disorder LLT
    19.0 100000004864 10074692 Post essential thrombocythaemia myelofibrosis LLT
    19.0 100000004864 10074690 Post essential thrombocythemia myelofibrosis LLT
    19.0 100000004864 10074691 Post polycythaemia vera myelofibrosis LLT
    19.0 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    19.0 100000004864 10015495 Essential thrombocytosis LLT
    19.0 100000004864 10015494 Essential thrombocythemia LLT
    19.0 100000004864 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001167-12 Sponsor Protocol Number: IMMUNED Start Date*: 2015-05-21
    Sponsor Name:University of Essen
    Full Title: A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanom...
    Medical condition: Stage IV melanoma with no evidence of disease after surgery or radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002740-85 Sponsor Protocol Number: BTI-01D-EC/12/ALO Start Date*: 2014-02-11
    Sponsor Name:BTI BIOTECHNOLOGY INSTITUTE IMASD
    Full Title: A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and...
    Medical condition: Androgenetic alopecia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003713-18 Sponsor Protocol Number: INCB18424-304 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BG (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001454-18 Sponsor Protocol Number: UG1617 Start Date*: 2016-10-05
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: T cell therapy for patients with advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002190-10 Sponsor Protocol Number: UCDCRC/20/03 Start Date*: 2021-02-05
    Sponsor Name:University College Dublin
    Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
    Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002807-32 Sponsor Protocol Number: CONTENT-0001 Start Date*: 2013-10-07
    Sponsor Name:Aarhus University Hospital, Department of Cardiology
    Full Title: Antibiotic treatment for patients with infectious endocarditis: continuous infusion, guided by therapeutic drug monitoring, versus intermittent infusions (the CONTENT study).
    Medical condition: Infectious Endocarditis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10000667 Acute and subacute infective endocarditis in diseases classified elsewhere LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000303-21 Sponsor Protocol Number: BIIT0115 Start Date*: 2015-06-24
    Sponsor Name:Biogen Idec Italia S.r.l.
    Full Title: A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in...
    Medical condition: Relapsing-remitting Multiple Sclerosis patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003193-14 Sponsor Protocol Number: DIAMOND Start Date*: 2017-10-03
    Sponsor Name:Department of Ophthalmology, MUW
    Full Title: Disease-modification under treatment with aflibercept in advanced diabetic retinopathy - A pilot study
    Medical condition: proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004917-15 Sponsor Protocol Number: RebOx Start Date*: 2020-04-22
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Reboxetine\Oxybutynin (AD128) Versus Placebo in Obstructive Sleep Apnea (RebOx)
    Medical condition: Obstructive Sleep Apnea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10040978 Sleep apnoeas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005305-73 Sponsor Protocol Number: CTHC1 Start Date*: 2012-07-06
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A rando...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008246-20 Sponsor Protocol Number: ABR 25995 Start Date*: Information not available in EudraCT
    Sponsor Name:Radboud University Nijmegen Medical Center, Department of Anaesthesiology, Pain and Palliative Medic
    Full Title: Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure.
    Medical condition: Sugammadex is a selective relaxant binding agent, which is administered in case of a rocuronium-induced neuromuscular block, during general anaesthesia. The aim of the trial is to investigate the u...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10009119 Chronic renal failure LLT
    9.1 10014647 End stage renal failure LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004122-33 Sponsor Protocol Number: HGB-207 Start Date*: 2016-11-10
    Sponsor Name:bluebird bio, Inc.
    Full Title: A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β-Thalassemia, who do not have β0/β0 Genotype, by Transplantation of Autologous ...
    Medical condition: This study will enroll subjects with transfusion dependent beta-thalassemia, who do not have beta0/beta0 genotype, defined by a history of at least 100 mL/kg/year of packed red blood cells (pRBCs) ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000868-29 Sponsor Protocol Number: V712-101 Start Date*: 2021-10-25
    Sponsor Name:DBV Technologies S.A.
    Full Title: Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase I Safety Study in Adult and Pediatric Subjects
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004792-50 Sponsor Protocol Number: C1502 Start Date*: 2017-08-22
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: Multi-centre, Double-blind, Randomised, Active- and Placebo-Controlled, Confirmatory Trial to Demonstrate Efficacy and Safety of Traumed® Gel in Patients having Acute Ankle Sprain
    Medical condition: Acute Ankle Sprain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000773-71 Sponsor Protocol Number: vem+IL-2v1.0 Start Date*: 2013-07-12
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1503  1504  1505  1506  1507  1508  1509  1510  1511  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 08:38:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA